We recently published a list of Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against Billionaire George Soros’ other small-cap stocks with huge upside potential.
When a legendary investor like George Soros makes a move, Wall Street pays attention. However, most of the limelight is taken by mega-cap stocks, with no one paying heed to the many small-cap stocks that form an important part of Soros’ portfolio.
Digging out these small-cap stocks is important. In some cases, these are the mega-cap stocks of the future. In other cases, these provide amazing returns in a very short period of time. The key is to get in early. And what better way to get in early than to do it when the big guys do.
We therefore decided to compile a list of stocks in billionaire George Soros’ portfolio that have the most upside. To come up with our list of billionaire George Soros’ 10 Small-Cap stocks with huge upside potential, we first looked at his top 50 stock holdings. We then filtered out the companies to look at only the ones with a market cap below $10 billion.
After arriving at his top small-cap holdings list, we then looked at the median analyst price targets on those stocks and then ranked them by their upside potential.
A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) operates as a commercial-stage biopharmaceutical company. The company targets development and discovery of gene therapies, RNA-targeted therapeutics, and other genetic therapeutic modalities. According to the median analyst price target, the stock still has an upside of 178.20%.
At the start of this month, the firm received an upgrade from H.C. Wainwright. Analysts upgraded the biopharma stock from Sell to Neutral and maintained their price target of $75. This upgrade was based on the expectations of strong earnings in Q1 2025. Regardless of safety concerns, they expect sustained demand for the drug, mainly among non-ambulatory and older patients, which is likely to benefit the company’s Q1 2025 earnings.
“After seeing the stock price reach our target ahead of schedule, we view the current valuation as in line ahead of 1Q25 results.”
Following this optimism, Wells Fargo initiated its coverage with an Overweight rating, highlighting the promising commercial potential of Elevidys. The firm assigned a target price of $115 to the stock.
Wells Fargo’s analyst Yanan Zhu stated:
“Elevidys remains the best option for most young DMD patients, and its commercial opportunity remains largely intact.”
Overall, SRPT ranks 1st on our list of billionaire George Soros’ small-cap stocks with huge upside potential. While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than SRPT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.